{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:22:09Z","timestamp":1786926129603,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.cgh.2017.08.006","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T14:46:02Z","timestamp":1502376362000},"page":"378-384.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline"],"prefix":"10.1016","volume":"16","author":[{"given":"Andrew J.","family":"Gawron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bielefeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.08.006_bib1","unstructured":"Drugs@FDA: FDA Approved Drug Products; 2015. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=206940). Accessed April 17, 2017."},{"key":"10.1016\/j.cgh.2017.08.006_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.08.006_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.08.006_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ajg.2016.542","article-title":"Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOG.0000000000000201","article-title":"Acute pancreatitis","volume":"31","author":"Talukdar","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2017.08.006_bib7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.japh.2016.11.011","article-title":"Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse","volume":"57","author":"Swank","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.cgh.2017.08.006_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bpg.2012.11.002","article-title":"Irritable bowel syndrome\u2013diarrhoea","volume":"26","author":"Wald","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2001.21908","article-title":"Management of the irritable bowel syndrome","volume":"120","author":"Camilleri","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.08.006_bib10","unstructured":"FDA Drug Safety Communication. FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder, 2017. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm546154.htm. Accessed April 17, 2017."},{"key":"10.1016\/j.cgh.2017.08.006_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/egh.09.27","article-title":"Current management and novel insights in acute pancreatitis","volume":"3","author":"Muddana","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.08.006_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2017.08.006_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0016-5085(84)90599-7","article-title":"Neural control of the sphincter of Oddi. Physiologic role of enkephalins on the regulation of basal sphincter of Oddi motor activity in the cat","volume":"86","author":"Behar","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.08.006_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/BF02093796","article-title":"Biliary motility. Changes in detailed characteristics correlated to duodenal migrating motor complex and effects of morphine and motilin in dogs","volume":"39","author":"Yokohata","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.08.006_bib15","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.3748\/wjg.v10.i19.2901","article-title":"Effects of narcotic analgesic drugs on human Oddi's sphincter motility","volume":"10","author":"Wu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib16","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clinre.2015.06.008","article-title":"Loperamide-induced recurrent acute pancreatitis","volume":"40","author":"Labgaa","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib17","first-page":"517414","article-title":"Loperamide-induced acute pancreatitis","volume":"2013","author":"Vidarsdottir","year":"2013","journal-title":"Case Rep Gastrointest Med"},{"key":"10.1016\/j.cgh.2017.08.006_bib18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/106002809603001121","article-title":"Pancreatitis caused by loperamide overdose","volume":"30","author":"Epelde","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cgh.2017.08.006_bib19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(85)91287-5","article-title":"Diphenoxylate and pancreatitis","volume":"1","author":"McCormick","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2017.08.006_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1572-0241.2001.03536.x","article-title":"Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis","volume":"96","author":"Thompson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000114852","article-title":"Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain","volume":"8","author":"Peiro","year":"2008","journal-title":"Pancreatology"},{"key":"10.1016\/j.cgh.2017.08.006_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/2303-9027.187892","article-title":"Opium-related sphincter of Oddi dysfunction causing double duct sign","volume":"5","author":"Sharma","year":"2016","journal-title":"Endosc Ultrasound"},{"key":"10.1016\/j.cgh.2017.08.006_bib23","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/MJT.0b013e3181baf253","article-title":"Sudden severe abdominal pain after a single low dose of paracetamol\/codeine in a cholecystectomized patient: learning from a case report","volume":"17","author":"Torres","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.cgh.2017.08.006_bib24","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1111\/j.1572-0241.2000.03213.x","article-title":"A\u00a0new source of drug-induced acute pancreatitis: codeine","volume":"95","author":"Hastier","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/EJA.0b013e32835953d0","article-title":"Is previous cholecystectomy a contraindication to paracetamol\/codeine premedication?","volume":"30","author":"Zahoor","year":"2013","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.cgh.2017.08.006_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.116.236547","article-title":"Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed \u03bc- and \u03ba-opioid receptor agonist and \u03b4-opioid receptor antagonist","volume":"359","author":"Levy-Cooperman","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2017.08.006_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2017.01.026","article-title":"Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea","volume":"15","author":"Fant","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.08.006_bib28","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/0016-5085(80)90924-5","article-title":"Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea","volume":"79","author":"Palmer","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.08.006_bib29","first-page":"402","article-title":"A\u00a0comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection","volume":"13","author":"Bergman","year":"1981","journal-title":"Ann Clin Res"},{"key":"10.1016\/j.cgh.2017.08.006_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000198057","article-title":"Long-term survey of the treatment of diarrhoea with loperamide","volume":"16","author":"Mainguet","year":"1977","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2017.08.006_bib31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/clpt.1980.239","article-title":"Abuse potential of loperamide","volume":"28","author":"Jaffe","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.08.006_bib32","first-page":"694","article-title":"Diphenoxylate-atropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature)","volume":"87","author":"McCarron","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.cgh.2017.08.006_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0253-7176.119474","article-title":"Lomotil (diphenoxylate) dependence in India","volume":"35","author":"Mehra","year":"2013","journal-title":"Indian J Psychol Med"},{"key":"10.1016\/j.cgh.2017.08.006_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","article-title":"International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit","volume":"43","author":"Drossman","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.08.006_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A\u00a0diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.08.006_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cgh.2015.09.027","article-title":"A\u00a0comprehensive self-management irritable bowel syndrome program produces sustainable changes in behavior after 1 year","volume":"14","author":"Zia","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.08.006_bib37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.brat.2010.03.003","article-title":"Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome - a randomized controlled trial","volume":"48","author":"Lj\u00f3tsson","year":"2010","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.cgh.2017.08.006_bib38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.12171","article-title":"Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention","volume":"37","author":"Labus","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517309357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517309357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:54Z","timestamp":1761542694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517309357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1542356517309357"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.08.006","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}